Once animal efficacy and toxicity have been established for a new compound, the next question is whether the compound has what it takes to get through development to human clinical trials. Understanding a compound’s “druggability” is critical to creating a strategy for formulation and manufacturing development. Compound “druggability” is measured by the solubility of the molecule, its bioavailability, ease of API synthesis and ease of manufacturing drug product. Pharmatek specializes in helping clients understand the druggability of their compounds prior to the start of drug development. We can help clients select among different drug candidates, whether they are analogs or new chemical entities. Pharmatek evaluates multiple parameters including:
Selecting the right compound to move forward is a critical step to a successful drug development campaign. Understanding the weaknesses of a compound prior to development can mean the difference between success and failure in the clinic. Pharmatek strives to provide critical knowledge to our clients so that these decisions are data driven. Our goal is to take the guesswork out of drug development.